Glucagon Injectable Trends and Forecast
The future of the global glucagon injectable market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global glucagon injectable market is expected to reach an estimated $1641.7 billion by 2030 with a CAGR of 3.5% from 2024 to 2030. The major drivers for this market are rising prevalence of diabetes, increased awareness of hypoglycemia, and government initiatives aimed at improving diabetes management and access to essential medication.
• Lucintel forecasts that, within the application category, therapeutic purpose will remain the larger segment over the forecast period.
• Within the distribution channel category, retail pharmacy is expected to witness the highest growth.
• In terms of regions, North America will remain the largest region over the forecast period due to the presence of the major market player and increasing senior population.
A more than 150-page report is developed to help in your business decisions.
Emerging Trends in the Glucagon Injectable Market
The market for glucagon injections is changing rapidly, improving the route and mode of application, and incorporating glucagon into the treatment of patients with diabetes. These trends are innovative, make treatment more accessible to patients, and elevate treatment outcomes, all aimed at improving diabetes management.
• Improved Delivery Systems: The introduction of auto-ejectors and prefilled syringe systems is changing how glucagon is administered to patients. Most of these over-the-counter marketed devices quickly enhance intervention due to compassion and are important for non-medical personnel to administer fast injections during moments of crisis, such as during unexpected hypoglycemia.
• Stable Formulations: Recent glucagon formulations that do not require refrigeration have improved patient comfort. Patients no longer need to store glucagon in the refrigerator, making it easier for those carrying glucagon to have it with them in case of an emergency.
• Integration with Telehealth: Telemedicine is changing the support and education strategies provided to patients regarding glucagon use. Tele-education improves how patients grasp and follow treatment guidelines.
• Focus on Patient Education: Many patients and caregivers are not well-informed about the use of glucagon, especially during a hypoglycemic attack. Awareness programs are helping people identify these signs and respond appropriately, thus improving their health.
• Combination Treatments Development: The search for ways to combine glucagon with other diabetes medicines continues, and new directions are opening up. Such integrated approaches allow more efficient management of patients with diabetes and improve glycemic control.
These new dimensions are improving the glucagon injectable market by providing easy-to-use and enhanced treatment options. With ongoing innovations, increasing support for people living with diabetes will improve and help in general health improvement.
Recent Developments in the Glucagon Injectable Market
Current changes in the glucagon injectable market are focusing on developments in product design, formulation, and delivery. These changes aim to improve the usability of glucagon during episodes of low blood sugar.
• The Launch of Auto-Injectors: The way glucagon injections are administered has undergone a major change thanks to auto-injectors. These devices make it easy for patients and caregivers to administer injections during hypoglycemic emergencies, thus improving patient safety and outcomes.
• Single-Use Ready-to-Administer Room-Temperature Stable Dry Powder Glucagon: The introduction of ready-to-use stable glucagon formulations that do not need temperature regulation or refrigeration is revolutionary. These are simple to use and comfortable for patients, especially in emergency situations, hence improving medication compliance.
• Improved Attention to Education: Companies are actively running educational programs for both patients and healthcare providers to enhance awareness regarding the management of hypoglycemia with glucagon. This initiative improves knowledge of correct usage and the advantages of the product.
• Expansion of Distribution Networks: Expanding distribution networks is making glucagon more accessible to patients, especially in underserved areas. This initiative addresses accessibility and enhances treatment compliance.
• Collaborations for Research and Development: The collaboration between pharmaceutical companies and research institutions is leading to the development of new glucagon products. These partnerships aim to create novel delivery methods and formulations, enhancing the quality of injectable glucagon dosage forms.
These recent changes have brought noticeable improvements to the glucagon injectable market by enhancing accessibility, improving safety, and creating awareness of the need for glucagon in treating hypoglycemic instability.
Strategic Growth Opportunities for Glucagon Injectable Market
The glucagon injectable market offers numerous strategic growth opportunities in various applications. These opportunities are driven by technological advancements, the rise in diabetes patients, and the need to manage hypoglycemia effectively.
• Expansion of Emergency Care Settings: The market for injectable glucagon can be expanded by extending its application into emergency care settings such as hospitals and clinics. Additionally, training healthcare workers on the use of glucagon may produce better outcomes.
• Home Care Management: The growth of home care and self-care by patients has created a market for glucagon products. Designing simpler devices for home use would improve acceptability and compliance.
• Pediatric Market Expansion: There is an increasing focus on manufacturing glucagon products for children with diabetes. Modifying formulations and methods of administration for children can help access this market.
• Telehealth Solutions: Utilizing telehealth services to educate and support glucagon use is a unique opportunity that remains untapped. Active patient participation can be enhanced through virtual consultations, enabling timely intervention.
• Combination Therapies: Combining glucagon with other therapeutic agents offers an opportunity for better management of patients. This approach addresses not only diabetes but also its multiple complications, making the product acceptable to more patients.
These strategic growth opportunities in the injectable glucagon market underscore the potential for manufacturers to impact diabetes management. By focusing on various applications, manufacturers can improve patient care and capture a wider market.
Glucagon Injectable Market Driver and Challenges
The glucagon injectable market is influenced by various drivers and challenges that shape its growth. Technological advancements, regulatory limitations, economic factors, and the changing healthcare landscape are some critical aspects.
The factors driving the glucagon injectable market include:
• Rising Diabetes Prevalence: The rise in diabetes cases worldwide has created a growing demand for new and better ways to manage hypoglycemia, including glucagon injectables, expanding the market for these products.
• Technological Advancements: The development of new glucagon formulations and delivery systems, such as auto-injectors and stable formulations, is increasing the efficiency and comfort of the product. These technologies are paving the way for market expansion.
• Growing Awareness and Education: Increasing awareness among both patients and healthcare providers about the significance of glucagon in managing diabetic emergencies is positively boosting the market and facilitating necessary interventions.
• Regulatory Support: Supportive regulatory policies and authorizations for the introduction of additional glucagon products are driving market development and fostering innovation among manufacturers, promoting healthy competition.
• Improved Healthcare Infrastructure: Enhanced healthcare infrastructure, especially in developing countries, will promote the use of glucagon injectables, increasing market share as availability improves patient adherence.
Challenges in the glucagon injectable market are:
• Cost and Affordability: The high cost of glucagon injections may prevent many individuals, especially in poorer regions, from accessing these injectables. This economic barrier impedes wider uptake.
• Need for Training: The proper administration of glucagon, especially during emergencies, requires appropriate education for healthcare providers, patients, and family members. Lack of education may delay administration.
• Competition from Alternatives: The growing number of alternative therapies for managing hypoglycemia may present a threat to glucagon injectables, requiring differentiation and innovation of the products.
In conclusion, the drivers and challenges in the glucagon injectable market highlight the need for continuous innovation and education. Finding viable solutions to these issues while taking advantage of the drivers will ultimately improve service delivery and contribute to the growth of the glucagon injectable market.
List of Glucagon Injectable Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies glucagon injectable companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the glucagon injectable companies profiled in this report include-
• Fresenius
• Xeris Pharmaceuticals
• Novo Nordisk
• ILS
• Amphastar Pharmaceuticals
• Lilly
• Avalon Pharma
Glucagon Injectable by Segment
The study includes a forecast for the global glucagon injectable by age group, route of administration, application, distribution channel, and region.
Glucagon Injectable Market by Age group [Analysis by Value from 2018 to 2030]:
• Pediatrics
• Adults
Glucagon Injectable Market by Route of administration [Analysis by Value from 2018 to 2030]:
• Subcutaneous
• Intramuscular
• Intravenous
Glucagon Injectable Market by Application [Analysis by Value from 2018 to 2030]:
• Therapeutic purpose
• Diagnostics purpose
Glucagon Injectable Market by Distribution Channel [Analysis by Value from 2018 to 2030]:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
Glucagon Injectable Market by Region [Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Glucagon Injectable Market
The glucagon injectable market is undergoing fundamental changes driven by growing diabetic and hypoglycemic populations, as well as new drug delivery technologies and formulation designs. In countries such as the United States, China, and Germany, significant advancements in glucagon products are focusing on patient comfort and effectiveness. These improvements are expanding treatment options and improving clinical outcomes, aligning with the general shift toward better and more convenient solutions for managing diabetic conditions.
• United States: In the US, the latest trends in the glucagon injectable market have been influenced by the introduction of user-friendly auto-injectors. These devices are being developed to administer medication to individuals other than healthcare professionals, which is crucial during acute hypoglycemia. Additionally, novel adjuvants approved by the FDA are expanding the scope of glucagon injectables, including non-refrigerated, stable glucagon formulations.
• China: The growth of the diabetes population is driving the expansion of the glucagon market in China. Efficient sales divisions have emerged following joint ventures between local and international producers of affordable glucagon prefilled syringes. Furthermore, promotional campaigns are enhancing healthcare providersÄX%$%X education on glucagonÄX%$%Xs role in treating hypoglycemia, thereby improving treatment and patient compliance.
• Germany: Germany is prioritizing the R&D of novel glucagon drugs with improved stability that do not require complex reconstitution. Additionally, combination therapies involving glucagon and other diabetic drugs are being launched. Increased investment in healthcare facilities is assisting in the distribution and availability of these novel glucagon products.
• India: The glucagon injectable market in India is evolving rapidly due to increased awareness and availability. The cost of glucagon is being reduced, making it more accessible for patients. Local companies are also producing ergonomic devices tailored to the characteristics of Indian patients.
• Japan: Japan is advancing in glucagon delivery devices, with startups focusing on portable emergency auto-injectors and compact formulations. Government campaigns to reduce diabetes complications are benefiting therapeutics. Pharmaceutical companies are also collaborating with tech companies to reform glucagon formulation and delivery methods.
Features of the Global Glucagon Injectable Market
Market Size Estimates: Glucagon injectable market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Glucagon injectable market size by various segments, such as by age group, route of administration, application, distribution channel, and region in terms of value ($B).
Regional Analysis: Glucagon injectable market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different age group, route of administration, application, distribution channel, and regions for the glucagon injectable market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the glucagon injectable market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What is the glucagon injectable market size?
Answer: The global glucagon injectable market is expected to reach an estimated $1641.7 billion by 2030.
Q2. What is the growth forecast for glucagon injectable market?
Answer: The global glucagon injectable market is expected to grow with a CAGR of 3.5% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the glucagon injectable market?
Answer: The major drivers for this market are rising prevalence of diabetes, increased awareness of hypoglycemia and government initiatives aimed at improving diabetes management and access to essential medication.
Q4. What are the major segments for glucagon injectable market?
Answer: The future of the glucagon injectable market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.
Q5. Who are the key glucagon injectable market companies?
Answer: Some of the key glucagon injectable companies are as follows:
• Fresenius
• Xeris Pharmaceuticals
• Novo Nordisk
• ILS
• Amphastar Pharmaceuticals
• Lilly
• Avalon Pharma
Q6. Which glucagon injectable market segment will be the largest in future?
Answer: Lucintel forecasts that therapeutic purpose will remain the larger segment over the forecast period.
Q7. In glucagon injectable market, which region is expected to be the largest in next 6 years?
Answer: North America will remain the largest region over the forecast period due to the presence of the major market player and increasing senior population.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the glucagon injectable market by age group (pediatrics and adults), route of administration (subcutaneous, intramuscular, and intravenous), application (therapeutic purpose and diagnostics purpose), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Glucagon Injectable Market, Glucagon Injectable Market Size, Glucagon Injectable Market Growth, Glucagon Injectable Market Analysis, Glucagon Injectable Market Report, Glucagon Injectable Market Share, Glucagon Injectable Market Trends, Glucagon Injectable Market Forecast, Glucagon Injectable Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.